{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:56:38Z","timestamp":1773762998888,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Provincial-level Talent Program for National Center of Technology Innovation for Biopharmaceuticals","award":["NCTIB2024JS0101"],"award-info":[{"award-number":["NCTIB2024JS0101"]}]},{"name":"Key Program for Basic Research in Jiangsu Province","award":["BK20243008"],"award-info":[{"award-number":["BK20243008"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82150106, 82473305"],"award-info":[{"award-number":["82150106, 82473305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Collaborative Innovation Center of Hematology"},{"name":"the Priority Academic Program Development of Jiangsu Higher Education Institutions"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02229-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:09:08Z","timestamp":1770822548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors"],"prefix":"10.1186","volume":"28","author":[{"given":"Xunyuan","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingkun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2229_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"2229_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298\u2013307.","journal-title":"Nature"},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58\u201362.","journal-title":"Science"},{"key":"2229_CR4","first-page":"1728","volume":"100","author":"Y Hayakawa","year":"2002","unstructured":"Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al. IFN-gamma-mediated Inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood. 2002;100:1728\u201333.","journal-title":"Blood"},{"key":"2229_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.it.2004.02.006","volume":"25","author":"P Romagnani","year":"2004","unstructured":"Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004;25:201\u20139.","journal-title":"Trends Immunol"},{"key":"2229_CR6","doi-asserted-by":"publisher","first-page":"e000154","DOI":"10.1136\/bmjonc-2023-000154","volume":"3","author":"MO Brian","year":"2024","unstructured":"Brian MO. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncol. 2024;3:e000154.","journal-title":"BMJ Oncol"},{"key":"2229_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncponc0403","volume":"3","author":"RK Jain","year":"2006","unstructured":"Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24\u201340.","journal-title":"Nat Clin Pract Oncol"},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus Paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376.","journal-title":"N Engl J Med"},{"key":"2229_CR9","doi-asserted-by":"crossref","unstructured":"Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K et al. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med. 2018;10(432):eaag0945.10.","DOI":"10.1126\/scitranslmed.aag0945"},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22:476\u201395.","journal-title":"Nat Rev Drug Discov"},{"key":"2229_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312.","journal-title":"Lancet"},{"key":"2229_CR12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a Third-Line or further treatment on overall survival of patients with advanced Non-Small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569\u201375.","journal-title":"JAMA Oncol"},{"key":"2229_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","volume":"6","author":"S Qin","year":"2021","unstructured":"Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:559\u201368.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2229_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","volume":"36","author":"RN Gacche","year":"2018","unstructured":"Gacche RN, Assaraf YG. Redundant angiogenic signaling and tumor drug resistance. Drug Resist Updat. 2018;36:47\u201376.","journal-title":"Drug Resist Updat"},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.critrevonc.2015.07.001","volume":"96","author":"V Ricci","year":"2015","unstructured":"Ricci V, Ronzoni M, Fabozzi T. Aflibercept a new target therapy in cancer treatment: a review. Crit Rev Oncol Hematol. 2015;96:569\u201376.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2229_CR16","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1158\/1078-0432.CCR-17-0647","volume":"23","author":"HJ Dalton","year":"2017","unstructured":"Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, et al. Macrophages facilitate resistance to Anti-VEGF therapy by altered VEGFR expression. Clin Cancer Res. 2017;23:7034\u201346.","journal-title":"Clin Cancer Res"},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ncb1288","volume":"7","author":"S Song","year":"2005","unstructured":"Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta\u2009+\u2009perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005;7:870\u20139.","journal-title":"Nat Cell Biol"},{"key":"2229_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.trecan.2017.05.002","volume":"3","author":"S Rey","year":"2017","unstructured":"Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting Hypoxia-Inducible factors for antiangiogenic cancer therapy. Trends Cancer. 2017;3:529\u201341.","journal-title":"Trends Cancer"},{"key":"2229_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell. 2020;37:471\u201384.","journal-title":"Cancer Cell"},{"key":"2229_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nm.3984","volume":"22","author":"N Andor","year":"2016","unstructured":"Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22:105\u201313.","journal-title":"Nat Med"},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;618:598\u2013606.","journal-title":"Nature"},{"key":"2229_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41588-021-00927-7","volume":"53","author":"R Chaligne","year":"2021","unstructured":"Chaligne R, Gaiti F, Silverbush D, Schiffman JS, Weisman HR, Kluegel L, et al. Epigenetic encoding, heritability and plasticity of glioma transcriptional cell States. Nat Genet. 2021;53:1469\u201379.","journal-title":"Nat Genet"},{"key":"2229_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41698-022-00251-1","volume":"6","author":"J Kim","year":"2022","unstructured":"Kim J, Park C, Kim KH, Kim EH, Kim H, Woo JK, et al. Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity. NPJ Precis Oncol. 2022;6:9.","journal-title":"NPJ Precis Oncol"},{"key":"2229_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"ZF Lim","year":"2019","unstructured":"Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12:134.","journal-title":"J Hematol Oncol"},{"key":"2229_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/JTO.0b013e318168be93","volume":"3","author":"A Sakurada","year":"2008","unstructured":"Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol. 2008;3:527\u20139.","journal-title":"J Thorac Oncol"},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","volume":"29","author":"T Botton","year":"2019","unstructured":"Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, et al. Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses. Cell Rep. 2019;29:573\u201388. e7.","journal-title":"Cell Rep"},{"key":"2229_CR27","doi-asserted-by":"publisher","first-page":"937924","DOI":"10.3389\/fimmu.2022.937924","volume":"13","author":"P Fan","year":"2022","unstructured":"Fan P, Qiang H, Liu Z, Zhao Q, Wang Y, Liu T, et al. Effective low-dose anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol. 2022;13:937924.","journal-title":"Front Immunol"},{"key":"2229_CR28","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/JCI96582","volume":"128","author":"X Zheng","year":"2018","unstructured":"Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, et al. Increased vessel perfusion predicts the efficacy of immune checkpoint Blockade. J Clin Invest. 2018;128:2104\u201315.","journal-title":"J Clin Invest"},{"key":"2229_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18:195\u2013203.","journal-title":"Nat Rev Immunol"},{"key":"2229_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250\u20134.","journal-title":"Nature"},{"key":"2229_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J, et al. Anlotinib induces a T Cell-Inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint Blockade in neuroblastoma. Clin Cancer Res. 2022;28:793\u2013809.","journal-title":"Clin Cancer Res"},{"key":"2229_CR32","doi-asserted-by":"publisher","first-page":"e20574","DOI":"10.1200\/JCO.2017.35.15_suppl.e20574","volume":"35","author":"WH Hu","year":"2017","unstructured":"Hu WH, Fang J, Nie J, Dai L, Zhang J, Chen XL, et al. Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma. J Clin Oncol. 2017;35:e20574\u2013e.","journal-title":"J Clin Oncol"},{"key":"2229_CR33","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.1073\/pnas.1710754114","volume":"114","author":"K Jung","year":"2017","unstructured":"Jung K, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, et al. Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. Proc Natl Acad Sci U S A. 2017;114:10455\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2229_CR34","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1038\/s41467-022-33991-6","volume":"13","author":"DK Kim","year":"2022","unstructured":"Kim DK, Jeong J, Lee DS, Hyeon DY, Park GW, Jeon S, et al. PD-L1-directed PlGF\/VEGF Blockade synergizes with chemotherapy by targeting CD141(+) cancer-associated fibroblasts in pancreatic cancer. Nat Commun. 2022;13:6292.","journal-title":"Nat Commun"},{"key":"2229_CR35","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205\u201318.","journal-title":"J Clin Oncol"},{"key":"2229_CR36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592\u2013603.","journal-title":"Nat Rev Cancer"},{"key":"2229_CR37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220\u201331.","journal-title":"Cancer Cell"},{"key":"2229_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"2229_CR39","doi-asserted-by":"publisher","first-page":"54173","DOI":"10.18632\/oncotarget.17013","volume":"8","author":"Z Fang","year":"2017","unstructured":"Fang Z, Wen C, Chen X, Yin R, Zhang C, Wang X, et al. Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. Oncotarget. 2017;8:54173\u201386.","journal-title":"Oncotarget"},{"key":"2229_CR40","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K. Normalization of the tumor microenvironment by Harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55:2308\u201319.","journal-title":"Exp Mol Med"},{"key":"2229_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O\u2019Brien SA, et al. Single-Cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442\u201359. e29.","journal-title":"Cell"},{"key":"2229_CR42","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1172\/JCI93182","volume":"127","author":"K Jung","year":"2017","unstructured":"Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest. 2017;127:3039\u201351.","journal-title":"J Clin Invest"},{"key":"2229_CR43","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.4110\/in.2021.21.e31","volume":"21","author":"J Jeong","year":"2021","unstructured":"Jeong J, Kim DK, Park JH, Park DJ, Lee HJ, Yang HK, et al. Tumor-infiltrating neutrophils and non-classical monocytes may be potential therapeutic targets for HER2(negative) gastric cancer. Immune Netw. 2021;21:e31.","journal-title":"Immune Netw"},{"key":"2229_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-024-01936-w","volume":"23","author":"J Kim","year":"2024","unstructured":"Kim J, Kim TJ, Chae S, Ha H, Park Y, Park S, et al. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 Blockade in melanoma. Mol Cancer. 2024;23:45.","journal-title":"Mol Cancer"},{"key":"2229_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"2229_CR46","doi-asserted-by":"crossref","unstructured":"Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L et al. DLL1 orchestrates CD8(+) T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci USA. 2021;118(22), p.e2020057118118.","DOI":"10.1073\/pnas.2020057118"},{"key":"2229_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1172\/JCI9775","volume":"107","author":"P Romagnani","year":"2001","unstructured":"Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest. 2001;107:53\u201363.","journal-title":"J Clin Invest"},{"key":"2229_CR48","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998\u20132006.","journal-title":"JAMA"},{"key":"2229_CR49","doi-asserted-by":"crossref","unstructured":"Guo L, Wang Y, Yang W, Wang C, Guo T, Yang J et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology. 2023;165:414\u2013428","DOI":"10.1053\/j.gastro.2023.04.029"},{"key":"2229_CR50","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an Open-Label, phase IIa multiple basket study. J Clin Oncol. 2018;36:536\u201342.","journal-title":"J Clin Oncol"},{"key":"2229_CR51","doi-asserted-by":"publisher","first-page":"e000473","DOI":"10.1136\/bmjonc-2024-000473","volume":"3","author":"Z Liu","year":"2024","unstructured":"Liu Z, Ma K, Jia Q, Yang Y, Fan P, Wang Y, et al. Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer. BMJ Oncol. 2024;3:e000473.","journal-title":"BMJ Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02229-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02229-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02229-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:03:56Z","timestamp":1773756236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02229-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02229-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal study was reviewed and approved by the Institutional LaboratoryAnimal Care and Use Committee of Soochow University","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"59"}}